AB-106

DRUG2 trials

Sponsors

Nuvation Bio Inc.

Conditions

Non Small Cell Lung CancerSolid Tumor

Phase 2

A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene

Active, not recruitingNCT04395677

Nuvation Bio Inc.Non Small Cell Lung Cancer

Start: 2020-07-07End: 2027-06-01Updated: 2026-02-06

Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fusion

TerminatedNCT04617054

Nuvation Bio Inc.Solid Tumor

Start: 2021-06-01End: 2024-12-06Updated: 2026-01-21

Related Papers

Patient-reported outcomes (PROs) and health-related quality of life (HRQoL) with taletrectinib in advanced ROS1+ non-small cell lung cancer (NSCLC) from the TRUST-II study.

Journal of Clinical Oncology2026-05-28

Long-Term Efficacy and Safety of Taletrectinib in Patients With <i>ROS1</i> + Non–Small Cell Lung Cancer: Results From the Phase II TRUST-I Study

Journal of Clinical Oncology2026-04-21

Abstract CT244: Taletrectinib in tyrosine kinase inhibitor (TKI)-pretreated patients with ROS1+ non-small cell lung cancer (NSCLC): Updated data from TRUST-I and TRUST-II

Cancer Research2026-04-17

Abstract CT300: Taletrectinib in tyrosine kinase inhibitor (TKI)-naïve patients with ROS1+ non-small cell lung cancer (NSCLC): Updated data from TRUST-I and TRUST-II

Cancer Research2026-04-17

Comparable efficacy and safety of taletrectinib for advanced ROS1+ non–small cell lung cancer across pivotal studies and between races and world regions.

Journal of Clinical Oncology2025-05-281 citations

Abstract 5612: Taletrectinib, a next generation selective ROS1 inhibitor, inhibits growth of ROS1 wild-type and ROS1-G2032R xenografts

Cancer Research2025-04-211 citations

Efficacy and Safety of Taletrectinib in Chinese Patients With <i>ROS1+</i> Non–Small Cell Lung Cancer: The Phase II TRUST-I Study

Journal of Clinical Oncology2024-06-0128 citations

Efficacy and safety of taletrectinib in patients with advanced or metastatic ROS1+ non–small cell lung cancer: The phase 2 TRUST-I study.

Journal of Clinical Oncology2024-06-01

The efficacy and safety of taletrectinib in patients with TKI-naïve or crizotinib-pretreated ROS1-positive non–small cell lung cancer (NSCLC).

Journal of Clinical Oncology2022-06-0112 citations

TRUST-II: A global phase II study for taletrectinib in <i>ROS1</i> fusion–positive lung cancer and other solid tumors.

Journal of Clinical Oncology2022-06-014 citations

Taletrectinib (AB-106; DS-6051b) in metastatic non-small cell lung cancer (NSCLC) patients with ROS1 fusion: Preliminary results of TRUST.

Journal of Clinical Oncology2021-05-2010 citations

Efficacy of Taletrectinib (AB-106/DS-6051b) in <i>ROS1+</i> NSCLC: An Updated Pooled Analysis of U.S. and Japan Phase 1 Studies.

2020-10-2133 citations